GRAIL's Q1 2026: Soaring Revenue, Narrowing Loss, FDA Approval

GRAILs Q1 2026 earnings report is impressive, with a 50% increase in Galleri test shipments and a 37% rise in screening revenue. Total revenue climbed by 28%, and net loss narrowed by 12%. The company is expanding partnerships, including Epic and Quest, and has FDA approval for Galleri. Provider adoption is growing, and the NHS-Galleri trial showed improved outcomes. CEO Robert Ragusa is retiring, and President Joshua Ofman will take over. Guidance remains steady, and GRAIL is poised to scale multi-cancer early detection nationwide. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6e40518e7c8e05f7